Ailux Appoints Maria Belvisi, Ph.D., as Chief Scientific Officer
* Professor Belvisi joins from AstraZeneca, where she served as Senior Vice President, Research & Development, Respiratory & Immunology and built one of the most productive early R&D organizations in global pharma, including leading tozorakimab from preclinical research through Phase 3 investme...
XtalPi Holdings Announces Full Year 2025 Annual Results
HONG KONG, March 25, 2026 /PRNewswire/ -- Financial Highlights: * Revenues for year 2025 were RMB802.6 million, representing a year-over-year increase of 201.2%. * Net profit for year 2025 reached reached RMB 134.6 million, while adjusted net profit amounted to RMB 258.2 million, making th...
XtalPi Holdings Limited to Announce 2025 Annual Results on March 25, 2026
CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced that it will report its annual results for t...
Leading Automation Capabilities of XtalPi Recognized by Global Chemical Giant - Successful Launch of Advanced Automated Workstation at BASF
SHANGHAI, Feb. 9, 2026 /PRNewswire/ -- Chemistry serves as the foundational pillar of material innovation and transformation. It supports and shapes almost every aspect of modern industries. Recently, XtalPi Inc. (2228.HK), a global leader in AI- and robotics driven research and development (R&D)...
XtalPi Convenes Global Experts to Shape the Future of Molecular Glue Drug Discovery: From Serendipity to Precision
* Global thought leaders presented cutting-edge research at the 2026 International Symposium on Molecular Glue Drug Discovery. * XtalPi unveils the AI-driven XGlue™ platform to enable rapid, closed-loop molecular glue drug discovery. * Cross-sector discussions emphasized the need for bridgin...
XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance Bispecific Antibody Development
SHANGHAI, Nov. 5, 2025 /PRNewswire/ -- Ailux, an innovator in AI-powered biologics and a wholly owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery, today announced a strategic platform-based collaboration with Eli Lilly and Company ("Lilly") to accelerate the discovery and...
XtalPi AI Drug Discovery Collaboration Reaches Milestone as PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
SHENZHEN, China, Sept. 9, 2025 /PRNewswire/ -- XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 c...
XtalPi Holdings Announces 2025 Interim Results
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: * Revenue surged 404% year over year to RMB 517 million in the first half of 2025. * Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. * XtalPi wa...
XtalPi Holdings Announces 2025 Interim Results
SHENZHEN, China, Aug. 27, 2025 /PRNewswire/ -- Key Highlights from the Financial Report: * Revenue surged 404% year over year to RMB 517 million in the first half of 2025. * Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. * XtalPi wa...
XtalPi Signs MOU with Dong-A ST for Joint Research and Development of Immunology and Inflammation Therapies
CAMBRIDGE, Mass., Aug. 20, 2025 /PRNewswire/ -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based o...
XtalPi Holdings Limited to Announce 2025 Interim Results on August 27, 2025
CAMBRIDGE, Mass., Aug. 18, 2025 /PRNewswire/ -- XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced that it will report its interim results for t...
XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and...
XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery and Materials Science Simulations
CAMBRIDGE, Mass., June 30, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced an expansion of its research collaboration with Pf...
XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform
CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Professor and renowned biopharma entrepreneur-investor Gregory...
XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration
CAMBRIDGE, Mass. and LIVERPOOL, United Kingdom, June 13, 2025 /PRNewswire/ -- XtalPi, a leading life sciences and new materials R&D platform powered by quantum physics, AI and robotics, today announced its acquisition of Liverpool ChiroChem (LCC), a pioneer in automated chiral chemistry technolog...
XtalPi and Kula Bio Forge Multi-Million USD Collaborative R&D Agreement to Advance AI-Driven Microbial Fertilizers in China and the Middle East
CAMBRIDGE, Mass., March 28, 2025 /PRNewswire/ -- XtalPi (2228.HK) today announced the official signing of a strategic R&D collaboration agreement with U.S.-based Kula Bio inBoston. This partnership initiates a joint research initiative worth multi-million USD, focused on developing the next gener...
UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
* Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process * These advancements have the potential to transform antibody discovery methods, broadening therapeutic applications and accelerating the development of in...
XtalPi and Sinar Mas Multiartha Launch Strategic Partnership to Revolutionize AI Across Asia-Pacific
SINGAPORE, Nov. 7, 2024 /PRNewswire/ -- XtalPi (2228.HK) has announced a strategic partnership withIndonesia's powerhouse, led by one of its prominent business pillar Sinar Mas Multiartha. This landmark collaboration is set to transform the future of artificial intelligence (AI) and robotics acro...
Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform
CAMBRIDGE, Mass., Oct. 12, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. ...
XtalPi Launches Computational Chemistry Software for Drug Discovery: XMolGen and XFEP
BOSTON and SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- Today, XtalPi announced the official launch of XFEP and XMolGen, two proprietary software products designed to accelerate and enhance the efficiency of drug discovery. Upon this launch, XtalPi will offer commercial licenses with flexible terms f...
